0.00Open0.00Pre Close0 Volume0 Open Interest2.00Strike Price0.00Turnover2702.60%IV-63.03%PremiumOct 11, 2024Expiry Date3.41Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9241Delta0.0224Gamma1.42Leverage Ratio-0.6654Theta0.0000Rho1.32Eff Leverage0.0003Vega
Inovio Pharmaceuticals Stock Discussion
On Friday, the fear of human-to-human spread grew ever so slightly: The CDC confirmed that four health-care workers in Missouri had fallen sick after caring for a patient who was infected with bird flu.
https://www.msn.com/en-us/health/other/bird-flu-pandemic-fears-skyrocket-as-us-identifies-first-cases-of-possible-human-to-human-transmission/ar-AA1rwhf5?ocid=BingNewsSerp
Inovio Receives Advanced Therapy Medicinal Product Certificate From European Medicines Agency for Quality and Non-Clinical Data for Lead Candidate Ino-3107
• BLA submission on track for INO-3107 in second half of 2024; if approved under accelerated approval pathway, could be first non-surgicaltreatment for recurrent respiratory papillomatosis (RRP)
• Planning initiation of confirmatory trial for INO-3107 based on FDA feedback
• Advancing plans for Phase 3 trial of INO-3112 in combination with LOQTORZITM ...
No comment yet